ALX Oncology Holdings Inc. Stock price

Equities

ALXO

US00166B1052

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
11.15 USD -2.28% Intraday chart for ALX Oncology Holdings Inc. -10.87% -25.12%
Sales 2024 * - Sales 2025 * - Capitalization 559M
Net income 2024 * -173M Net income 2025 * -171M EV / Sales 2024 * -
Net Debt 2024 * 952K Net Debt 2025 * 13.89M EV / Sales 2025 * -
P/E ratio 2024 *
-3.41 x
P/E ratio 2025 *
-3.95 x
Employees 72
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.9%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.28%
1 week-10.87%
Current month-23.99%
1 month-23.16%
3 months-27.05%
6 months+125.25%
Current year-25.12%
More quotes
1 week
10.60
Extreme 10.6
12.17
1 month
10.60
Extreme 10.6
16.39
Current year
10.60
Extreme 10.6
17.42
1 year
3.94
Extreme 3.9357
17.42
3 years
3.94
Extreme 3.9357
81.19
5 years
3.94
Extreme 3.9357
117.45
10 years
3.94
Extreme 3.9357
117.45
More quotes
Managers TitleAgeSince
Founder 58 15-03-31
Chief Executive Officer 46 20-03-31
Director of Finance/CFO 62 19-12-31
Members of the board TitleAgeSince
Director/Board Member 55 22-11-27
Chairman 72 15-02-28
Director/Board Member 60 20-03-31
More insiders
Date Price Change Volume
24-03-28 11.15 -2.28% 1,184,876
24-03-27 11.41 +1.97% 197,181
24-03-26 11.19 -4.52% 261,983
24-03-25 11.72 -0.17% 268,811
24-03-22 11.74 -6.16% 525,141

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
11.15 USD
Average target price
20.17 USD
Spread / Average Target
+80.87%
Consensus
  1. Stock
  2. Equities
  3. Stock ALX Oncology Holdings Inc. - Nasdaq